Trial Profile
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Venglustat (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi Genzyme
- 08 Jan 2019 Status changed from active, no longer recruiting to completed.
- 29 Nov 2018 Planned End Date changed from 15 Nov 2018 to 1 Nov 2018.
- 29 Nov 2018 Planned primary completion date changed from 15 Nov 2018 to 1 Nov 2018.